Litigation Details for Hospira, Inc. v. Fresenius Kabi USA, LLC (N.D. Ill. 2017)
✉ Email this page to a colleague
Hospira, Inc. v. Fresenius Kabi USA, LLC (N.D. Ill. 2017)
Docket | ⤷ Sign Up | Date Filed | 2017-11-01 |
Court | District Court, N.D. Illinois | Date Terminated | 2018-12-16 |
Cause | 35:271 Patent Infringement | Assigned To | Rebecca R. Pallmeyer |
Jury Demand | None | Referred To | |
Patents | 8,242,158; 8,338,470; 8,455,527; 8,648,106; 9,320,712; 9,616,049 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Hospira, Inc. v. Fresenius Kabi USA, LLC
Details for Hospira, Inc. v. Fresenius Kabi USA, LLC (N.D. Ill. 2017)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2017-11-01 | 1 | infringement of U.S. Patent No. 9,616,049 (the “’049 patent”) (Ex. A) (the “Patent-in-suit”). … COUNT I FOR INFRINGEMENT OF PATENT NO. 9,616,049 17. Paragraphs 1 through… THE PATENT-IN-SUIT 9. The ’049 patent, entitled “Dexmedetomidine…assignee and owner of the ’049 patent. 10. The Patent-in-suit is duly listed in the… 4. This action is based upon the Patent Laws of the United States, 35 U.S.C. § 1 et seq | External link to document | |
2018-12-16 | 109 | Order on Motion for Partial Summary Judgment | obtained four patents covering a new product made from dexmedetomidine: U.S. Patent Nos. 8,242,158 (the “’158…’158 Patent”), 8,338,470 (the “’470 Patent”), 8,455,527 (the “’527 Patent”), and 8,648,106 (the “’106…product—U.S. Patent No. 9,616,049 (the “’049 Patent”)—and filed a second complaint of patent infringement…obtained a patent that disclosed and claimed the compound: U.S. Patent No. 4,910,214 (the “’214 Patent”), JTX…named co- inventors of the patents-in-suit. (See ’106 Patent, JTX 1; ’049 Patent, JTX 2.) Dr. Roychowdhury | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |